A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

Journal: Nature Communications • • Nature Portfolio • ISSN: 2041-1723

Abstract

Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets that make resistant cells susceptible to dual inhibition of BET and CBP/p300 signaling.

Subjects & Keywords

How to Cite this Article

Yundong He, Ting Wei, Zhenqing Ye, et al. (2021). "A noncanonical AR addiction drives enzalutamide resistance in prostate cancer". Nature Communications. https://doi.org/10.1038/s41467-021-21860-7